Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals — Q1 2018 Earnings Presentation

21 slides from Avadel Pharmaceuticals's earnings presentation, May 2, 2018

  1. Slide 1: First Quarter 2018 Earnings Conference Call

    First Quarter 2018 Earnings Conference Call May 2, 2018

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words “will,” “may,” “believe,” “expect,” “anticipate,” “estimate,” “project” and similar expressions, and

  3. Slide 3: 1Q 2018 Call Outline

    1Q 2018 Call Outline I. 1Q overview of strategic progress II. REST-ON Phase III trial III. NOCTIVA™ launch update IV. Hospital products & development update V. Financial Results I. GAAP Results II. Non-GAAP Results III. Cash Flow IV. 2018 Guidance 3

  4. Slide 4: Strategic Execution

    Strategic Execution 1Q 2018 revenues of $33.3 million & adjusted LPS of $(0.34) Granted Orphan Drug Designation for FT 218 & increased REST-ON trial enrollment Divested four pediatric products to Cerecor, Inc. Launched NOCTIVA to the trade four weeks ahead of schedule $138.4 million in net proceeds

  5. Slide 5: REST-ON Phase III Trial

    \ Avadel” REST-ON Phase III Trial

  6. Slide 6: REST-ON Status Update

    REST-ON Status Update Trial enrollment is active and improving Recent enrollment trends have increased almost 30% Australian sites in process of being initiated – opportunity to provide more sodium oxybate naïve patients Update on trial to be provided in 2H 2018 Ongoing clinical work to support robu

  7. Slide 7: NOCTIVA Launch Update

    ®Avadel” NOCTIVA™ Launch Update

  8. Slide 8: NOCTIVA: Launch Update

    NOCTIVA™: Launch Update • 20k sales calls and over 600,000 print & digital engagement impressions reaching over 90% of our target audience • Exclusive partnerships with the leading clinical and scientific educational platforms • Unique, therapeutic category for NOCTIVA in leading compendium – NO the

  9. Slide 9: Hospital Products & Development Update

    Hospital Products & Development Update Bloxiverz®, Akovaz®, and Vazculep® continue to provide us with high margin sales Leading market share positions across all products Provided opportunity to fund our clinical work, acquire NOCTIVA & raise capital Developing fourth sterile injectable product est.

  10. Slide 10: First Quarter 2018 Financial Results

    First Quarter 2018 Financial Results 10

  11. Slide 11: Items of Note

    Items of Note First quarter revenue was $33.3 million – above consensus; Reiterate 2018 guidance Settled Deerfield warrants – we received $2.9 M in cash & issued ~603,000 shares; over last 12 months reduced shares outstanding ~12% Hospital products still carry over 85% gross margins Cash balance alm

  12. Slide 12: Non-GAAP Financial Results

    Non-GAAP Financial Results *Reconciliations from GAAP to Non-GAAP can be found in the appendix Three Months Ended (in $000s, except for per share amounts 03/31/18 12/31/17 03/31/17 Total revenues $ 33,293 $ 35,094 $ 52,507 Cost of products 6,592 4,048 3,856 Research and development expenses 9,951 11

  13. Slide 13: GAAP Financial Results

    GAAP Financial Results Three Months Ended (in $000s, except for per share amounts 03/31/18 12/31/17 03/31/17 Total revenues $ 33,293 $ 34,752 $ 52,507 Cost of products 6,592 4,048 3,902 Research and development expenses 9,951 11,325 7,206 Selling, general and admin expenses 24,487 23,056 11,812 Inta

  14. Slide 14: Cash Flow Summary

    Cash Flow Summary in $000's Three Months ended March 31, 2018 2017 TOTAL Cash and Marketable Securities Beginning Balance $ 94,075 $ 154,195 Operating cash flows (excl Noctiva and earnouts) 3,504 33,477 Noctiva operating spending (14,897) - Earnout payments (6,615) (8,169) Total Operating Cash Flows

  15. Slide 15: 2018 Guidance Reaffirmed

    2018 Non-GAAP Guidance 2018 Guidance Range Total Revenue $105M - $125M Noctiva Revenues $10M - $20M R&D Expense $40M - $50M SG&A Expense $80M - $90M Income Tax Benefit 0% - 10% 2018 Guidance Reaffirmed 15

  16. Slide 16: Question & Answer

    u ™ w Avadel Question & Answer

  17. Slide 17: Appendix

    u ™ w Avadel Appendix

  18. Slide 18: Revenues by Product (GAAP)

    Revenues by Product (GAAP) i n $000's Q1 2018 Q4 2017 Q1 2017 Bloxiverz $ 7,491 $ 8,055 $ 13,902 Vazculep 12,961 8,281 10,179 Akovaz 10,217 15,507 25,638 Noctiva 666 - - Other 1,826 2,989 2,038 Total product sales $ 33,161 $ 34,832 $ 51,757 License revenue 132 (80) 750 Total revenues $ 33,293 $ 34,7

  19. Slide 19: GAAP to Non-GAAP Reconciliations

    GAAP to Non-GAAP Reconciliations GAAP to Non-GAAP adjustments for the three months ended March 31, 2018 Exclude Include Contingent related party Contingent Foreign Equity Securities Exchangeable payable related party Intangible asset exchange (loss) Restructuring unrealized Notes interest fair value

  20. Slide 20: GAAP to Non-GAAP Reconciliations

    GAAP to Non-GAAP Reconciliations GAAP to Non-GAAP adjustments for the three months ended December 31, 2017 Exclude Include Contingent related party Contingent Foreign payable related party Intangible asset exchange Restructuring U.S. Income Tax License Revenue fair value payable Total GAAP amortizat

  21. Slide 21: GAAP to Non-GAAP Reconciliations

    GAAP to Non-GAAP Reconciliations GAAP to Non-GAAP adjustments for the three months ended March 31, 2017 Exclude Include Contingent Purchase related party Contingent Foreign accounting payable related party Intangible asset exchange (loss) Restructuring adjustments - fair value payable Total GAAP amo

Avadel Pharmaceuticals — Q1 2018 Earnings Presentation on 6ix